Research and Discovery

WHOLE EXOME SEQUENCING

Analyzing the complete coding sequences in Human, Mouse, Canine and Zebra Fish

 


Clinical Genetic Testing

GENOMIC MEDICINE

DNA and RNA sequencing to identify the molecular fingerprint of a patient for Precision Medicine

 

Research and Discovery

RNA SEQUENCING

Profiling gene expression to reveal alternative splicing, structural variations and novel transcripts

 


Clinical Genetic Testing

REPRODUCTIVE MEDICINE

Providing parents with meaningful information to guide pregnancy planning 

 

Research and Discovery

CLINICAL TRIALS

Assess drug treatment efficacy and guide healthcare decision making

 


Clinical Genetic Testing

HEREDITARY CANCER RISK ASSESSMENT

 Genetic testing can identify at-risk patients and their family members

 

Research and Discovery

DISEASE GENE TESTING

Comprehensive NGS service for disease associated genes 

 


Clinical Genetic Testing

PHARMACOGENOMICS

Your genetic make-up affects your response to medication.  Personalized medication choices to increase drug efficiency and reduce adverse reactions

 

Research and Discovery

BIOMARKER IDENTIFICATION

Discover potential disease biomarkers

 


Clinical Genetic Testing

  HEARING LOSS & NEWBORN SCREENING 

  Gene testing for better outcomes and language development 

 

Research and Discovery

NUTRITIONAL GENOMICS

Gene-Disease-Diet and risks for obesity, diabetes, cardiovascular diseases 

 


Clinical Genetic Testing

CARDIOMYOPATHY

Identify genetic factors of heart disease in all age groups 

 

Research and Discovery

ADDITIONAL NEXT GENERATION SEQUENCING

Flexible approaches for your NGS projects 

 


Clinical Genetic Testing

CLINICAL EXOME SEQUENCING

Determine novel disease-causing DNA variants 

 

Otogenetics is a Next Generation Sequencing (NGS) laboratory service provider established by two professors from Emory University School of Medicine in 2007 with NIH funding.  The company developed and launched a Newborn Screening Hearing Loss Panel sequencing 167 genes associated with Syndromic and Non-Syndromic Hearing Loss.  Our test offering now includes Genomic Medicine, Hereditary Cancer Risk Assessment, Expanded Carrier Screening, Pharmacogenomics & Personalized Medicine, Cardiomyopathy, and Whole Exome & RNA Sequencing for precision treatment of tumors, and testing for Rare Diseases.  Disease panels are custom designed for both research collaborators and clinical diagnostics.

Test results for genetic diagnoses and risk assessment using NGS technologies resulted in publications in highly reputable biomedical journals including Nature and Nature Medicine; attesting to the high caliber and quality of the gene panel design offered by the company.  Otogenetics also assists medical schools in training a new generation of medical students in Precision Medicine.

Publications & Press Releases

Somatic activating mutations in MAP2K1 cause melorheostosis

Deep Exome Sequencing by Otogenetics for Clinical Researchers leads to discovery of key somatic mutations in MAP2K1 in melorheostotic* bones of patients. (*Melorheosis is characterized by excess bone formation on the surface of the bone. The bone overgrowth lesions are…

Otogenetics helps clinicians in discovery of a novel autosomal dominant hearing loss mutation

Otogenetics hearing loss gene test lend the tool for clinicians to discover an autosomal dominant hearing loss mutation in POU4F3 gene. This particular variant t cosegregated with hearing loss in family members but was not detected in 580 normal hearing…

Cancer Marker Identification Using Otogenetics NGS Service

Combined mutation in Vhl, Trp53 and Rb1 causes clear cell renal cell carcinoma in mice Read the full article here

Otogenetics Helps Educating a New Generation of Medical Students with Cadaver Exome Sequencing.

US life expectancy varies > 20 years regionally. Access to quality healthcare, such as early cancer screening, is a contributing factor. Check out the new study published in JAMA Internal Medicine (May 8, 2017), and check out Gx™ cancer genetic screening.